<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804206</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-040</org_study_id>
    <nct_id>NCT00804206</nct_id>
  </id_info>
  <brief_title>Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation</brief_title>
  <official_title>Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Compare the effect of an intravitreal injection of bevacizumab previous or posterior of
      panretinal laser photocoagulation (PRLP) with a pattern laser; to prevent and reduce diabetic
      macular edema (DME) in patients with proliferative diabetic retinopathy (PDR) with DME.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central macular thickness</measure>
    <time_frame>baseline, 10 days, 52 days, 85 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>baseline, 10 days, 52 days, 85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab before panretinal photocoagulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab after panretinal photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravitreal bevacizumab before panretinal photocoagulation</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravitreal Bevacizumab after panretinal photocoagulation</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with proliferative diabetic retinopathy

          -  patients with macular edema

        Exclusion Criteria:

          -  patients with previous treatments

          -  patients with ocular surgeries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miriam Jessica López-Miranda, MD</last_name>
    <phone>10841400</phone>
    <phone_ext>1171</phone_ext>
    <email>jessicalop@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México</name>
      <address>
        <city>México</city>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Jessica López-Miranda, MD</last_name>
      <phone>10841400</phone>
      <phone_ext>1171</phone_ext>
      <email>jessicalop@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Hernandez-Miranda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Jessica López-Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Luis Guerrero-Naranjo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>December 5, 2008</last_update_submitted>
  <last_update_submitted_qc>December 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Asociación para evitar la ceguera en mexico</name_title>
    <organization>APEC</organization>
  </responsible_party>
  <keyword>Intravitreal injection of Bevacizumab</keyword>
  <keyword>Visual acuity</keyword>
  <keyword>central retinal thickness</keyword>
  <keyword>color studies, Farnsworth-Munsell</keyword>
  <keyword>electroretinogram studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

